PLUS1
18.67
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| AnaptysBio Inc | ANAB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 18.67 | 0.00 | 0.00 | 0.00 | 18.67 | 20:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 18.30 | 19.50 | 1.20 | 6.15% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 18.67 | USD |
AnaptysBio Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 509.26M | 27.28M | 26.79M | $ 8.00M | $ - | -3.61 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 9.00 | 1.80% |
AnaptysBio News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/06/2020 | 16:15 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 5/06/2020 | 16:12 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 5/06/2020 | 16:05 | GlobeNewswire Inc. | AnaptysBio Announces First Quarter 2020 Financial Results.. |
| 4/29/2020 | 19:26 | Business Wire | Shareholder Alert: Robbins LLP Announces It Is Investigating.. |
| 4/27/2020 | 16:04 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) |
| 4/27/2020 | 16:03 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) |
| 4/09/2020 | 14:20 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ANAB Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 19.10 | 21.31 | 18.00 | 19.31 | 432,279 | -0.43 | -2.25% |
| 1 Month | 17.84 | 21.31 | 17.5679 | 19.32 | 352,929 | 0.83 | 4.65% |
| 3 Months | 14.45 | 21.31 | 12.06 | 15.90 | 458,540 | 4.22 | 29.2% |
| 6 Months | 14.51 | 21.31 | 11.95 | 15.70 | 518,066 | 4.16 | 28.67% |
| 1 Year | 74.03 | 77.285 | 9.16 | 21.59 | 544,424 | -55.36 | -74.78% |
| 3 Years | 24.95 | 134.00 | 9.16 | 51.11 | 395,484 | -6.28 | -25.17% |
| 5 Years | 16.00 | 134.00 | 9.16 | 50.15 | 366,188 | 2.67 | 16.69% |
AnaptysBio Description
| AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements. |
